Search Results - "Peled, Nir"

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer by Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G, Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O’Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leiby, Melanie A, Lubiniecki, Gregory M, Shentu, Yue, Rangwala, Reshma, Brahmer, Julie R

“…In a randomized trial involving patients with previously untreated advanced non–small-cell lung cancer, pembrolizumab was associated with a higher response…”
Get full text

Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways by Hakim, Meggie, Broza, Yoav Y, Barash, Orna, Peled, Nir, Phillips, Michael, Amann, Anton, Haick, Hossam

“…Hakim et al examine the volatile organic compounds of lung cancer and possible biochemical pathways…”
Get full text

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer by Gadgeel, Shirish, Rodríguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Dómine, Manuel, Hui, Rina, Hochmair, Maximilian J, Clingan, Philip, Powell, Steven F, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Garon, Edward B, Novello, Silvia, Rubio-Viqueira, Belén, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E, Yang, Jing, Bas, Tuba, Pietanza, M Catherine, Garassino, Marina C

“…In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared…”
Get full text

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges by Seijo, Luis M, Peled, Nir, Ajona, Daniel, Boeri, Mattia, Field, John K, Sozzi, Gabriella, Pio, Ruben, Zulueta, Javier J, Spira, Avrum, Massion, Pierre P, Mazzone, Peter J, Montuenga, Luis M

“…The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two…”
Get more information

Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules by Nakhleh, Morad K, Amal, Haitham, Jeries, Raneen, Broza, Yoav Y, Aboud, Manal, Gharra, Alaa, Ivgi, Hodaya, Khatib, Salam, Badarneh, Shifaa, Har-Shai, Lior, Glass-Marmor, Lea, Lejbkowicz, Izabella, Miller, Ariel, Badarny, Samih, Winer, Raz, Finberg, John, Cohen-Kaminsky, Sylvia, Perros, Frédéric, Montani, David, Girerd, Barbara, Garcia, Gilles, Simonneau, Gérald, Nakhoul, Farid, Baram, Shira, Salim, Raed, Hakim, Marwan, Gruber, Maayan, Ronen, Ohad, Marshak, Tal, Doweck, Ilana, Nativ, Ofer, Bahouth, Zaher, Shi, Da-you, Zhang, Wei, Hua, Qing-ling, Pan, Yue-yin, Tao, Li, Liu, Hu, Karban, Amir, Koifman, Eduard, Rainis, Tova, Skapars, Roberts, Sivins, Armands, Ancans, Guntis, Liepniece-Karele, Inta, Kikuste, Ilze, Lasina, Ieva, Tolmanis, Ivars, Johnson, Douglas, Millstone, Stuart Z, Fulton, Jennifer, Wells, John W, Wilf, Larry H, Humbert, Marc, Leja, Marcis, Peled, Nir, Haick, Hossam

“…We report on an artificially intelligent nanoarray based on molecularly modified gold nanoparticles and a random network of single-walled carbon nanotubes for…”
Get full text

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma by Lu, Xinyuan, Peled, Nir, Greer, John, Wu, Wei, Choi, Peter, Berger, Alice H, Wong, Sergio, Jen, Kuang-Yu, Seo, Youngho, Hann, Byron, Brooks, Angela, Meyerson, Matthew, Collisson, Eric A

“…Targeting somatically activated oncogenes has revolutionized the treatment of non-small cell lung cancer (NSCLC). Mutations in the gene mesenchymal-epithelial…”
Get full text

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel by Willis, Jason, Lefterova, Martina I, Artyomenko, Alexander, Kasi, Pashtoon Murtaza, Nakamura, Yoshiaki, Mody, Kabir, Catenacci, Daniel V T, Fakih, Marwan, Barbacioru, Catalin, Zhao, Jing, Sikora, Marcin, Fairclough, Stephen R, Lee, Hyuk, Kim, Kyoung-Mee, Kim, Seung Tae, Kim, Jinchul, Gavino, Danielle, Benavides, Manuel, Peled, Nir, Nguyen, Timmy, Cusnir, Mike, Eskander, Ramez N, Azzi, Georges, Yoshino, Takayuki, Banks, Kimberly C, Raymond, Victoria M, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli, Kopetz, Scott, Lee, Jeeyun, Odegaard, Justin I

“…To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing. Pan-cancer MSI detection using…”
Get full text

Classification of lung cancer histology by gold nanoparticle sensors by Barash, Orna, MSc, Peled, Nir, MD, PhD, Tisch, Ulrike, PhD, Bunn, Paul A., MD, Hirsch, Fred R., MD, PhD, Haick, Hossam, PhD

“…Abstract We propose a nanomedical device for the classification of lung cancer (LC) histology. The device profiles volatile organic compounds (VOCs) in the…”
Get full text

Silicon Nanowire Sensors Enable Diagnosis of Patients via Exhaled Breath by Shehada, Nisreen, Cancilla, John C, Torrecilla, Jose S, Pariente, Enrique S, Brönstrup, Gerald, Christiansen, Silke, Johnson, Douglas W, Leja, Marcis, Davies, Michael P. A, Liran, Ori, Peled, Nir, Haick, Hossam

“…Two of the biggest challenges in medicine today are the need to detect diseases in a noninvasive manner and to differentiate between patients using a single…”
Get full text

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC by Riess, Jonathan W, Gandara, David R, Frampton, Garrett M, Madison, Russell, Peled, Nir, Bufill, Jose A, Dy, Grace K, Ou, Sai-Hong Ignatius, Stephens, Philip J, McPherson, John D, Lara, Jr, Primo N, Burich, Rebekah A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Mack, Philip C, Schrock, Alexa B

“…EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR…”
Get more information

ESR/ERS statement paper on lung cancer screening by Kauczor, Hans-Ulrich, Baird, Anne-Marie, Blum, Torsten Gerriet, Bonomo, Lorenzo, Bostantzoglou, Clementine, Burghuber, Otto, Čepická, Blanka, Comanescu, Alina, Couraud, Sébastien, Devaraj, Anand, Jespersen, Vagn, Morozov, Sergey, Agmon, Inbar Nardi, Peled, Nir, Powell, Pippa, Prosch, Helmut, Ravara, Sofia, Rawlinson, Janette, Revel, Marie-Pierre, Silva, Mario, Snoeckx, Annemiek, van Ginneken, Bram, van Meerbeeck, Jan P., Vardavas, Constantine, von Stackelberg, Oyunbileg, Gaga, Mina

“…In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of…”
Get full text

Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer by Rozenblum, Anna Belilovski, Ilouze, Maya, Dudnik, Elizabeth, Dvir, Addie, Soussan-Gutman, Lior, Geva, Smadar, Peled, Nir

“…Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor…”
Get more information

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models by Engstrom, Lars D, Aranda, Ruth, Lee, Matthew, Tovar, Elizabeth A, Essenburg, Curt J, Madaj, Zachary, Chiang, Harrah, Briere, David, Hallin, Jill, Lopez-Casas, Pedro P, Baños, Natalia, Menendez, Camino, Hidalgo, Manuel, Tassell, Vanessa, Chao, Richard, Chudova, Darya I, Lanman, Richard B, Olson, Peter, Bazhenova, Lyudmilla, Patel, Sandip Pravin, Graveel, Carrie, Nishino, Mizuki, Shapiro, Geoffrey I, Peled, Nir, Awad, Mark M, Jänne, Pasi A, Christensen, James G

“…exon 14 deletion ( ex14 del) mutations represent a novel class of non-small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a…”
Get full text

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data by Dudnik, Elizabeth, Moskovitz, Mor, Daher, Sameh, Shamai, Sivan, Hanovich, Ekaterina, Grubstein, Ahuva, Shochat, Tzippy, Wollner, Mira, Bar, Jair, Merimsky, Ofer, Zer, Alona, Goldstein, Daniel A., Hammerman, Ariel, Cyjon, Arnold, Shechtman, Yelena, Abu-Amna, Mahmood, Flex, Dov, Roisman, Laila C., Peled, Nir

“…•This series illustrates treatment outcomes with nivolumab in a real life setting.•The only variable which significantly correlated with OS was ECOG PS.•mOS…”
Get full text

The interaction of mast cells with membranes from lung cancer cells induces the release of extracellular vesicles with a unique miRNA signature by Shemesh, Rachel, Laufer-Geva, Smadar, Gorzalczany, Yaara, Anoze, Alaa, Sagi-Eisenberg, Ronit, Peled, Nir, Roisman, Laila C.

“…Mast cells (MCs) are immune cells that play roles in both normal and abnormal processes. They have been linked to tumor progression in several types of cancer,…”
Get full text

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling by Schrock, Alexa B, Li, Shuyu D, Frampton, Garrett M, Suh, James, Braun, Eduardo, Mehra, Ranee, Buck, Steven C, Bufill, Jose A, Peled, Nir, Karim, Nagla Abdel, Hsieh, K Cynthia, Doria, Manuel, Knost, James, Chen, Rong, Ou, Sai-Hong Ignatius, Ross, Jeffrey S, Stephens, Philip J, Fishkin, Paul, Miller, Vincent A, Ali, Siraj M, Halmos, Balazs, Liu, Jane J

“…Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic…”
Get more information

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next‐Generation Sequencing for Detection of EML4‐ALK Rearrangement in Lung Cancer by Pekar‐Zlotin, Marina, Hirsch, Fred R., Soussan‐Gutman, Lior, Ilouze, Maya, Dvir, Addie, Boyle, Theresa, Wynes, Murry, Miller, Vincent A., Lipson, Doron, Palmer, Gary A., Ali, Siraj M., Dekel, Shlomi, Brenner, Ronen, Bunn, Paul A., Peled, Nir

“…Background. The U.S. Food and Drug Administration‐approved method for detecting EML4‐ALK rearrangement is fluorescence in situ hybridization (FISH); however,…”
Get full text

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer by Rotow, Julia K, Gui, Philippe, Wu, Wei, Raymond, Victoria M, Lanman, Richard B, Kaye, Frederic J, Peled, Nir, Fece de la Cruz, Ferran, Nadres, Brandon, Corcoran, Ryan B, Yeh, Iwei, Bastian, Boris C, Starostik, Petr, Newsom, Kimberly, Olivas, Victor R, Wolff, Alexander M, Fraser, James S, Collisson, Eric A, McCoach, Caroline E, Camidge, D Ross, Pacheco, Jose, Bazhenova, Lyudmila, Li, Tianhong, Bivona, Trever G, Blakely, Collin M

“…Although patients with advanced-stage non-small cell lung cancers (NSCLC) harboring exon 14 skipping mutations ( ex14) often benefit from MET tyrosine kinase…”
Get full text

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016 by Tan, Daniel S W, Yom, Sue S, Tsao, Ming S, Pass, Harvey I, Kelly, Karen, Peled, Nir, Yung, Rex C, Wistuba, Ignacio I, Yatabe, Yasushi, Unger, Michael, Mack, Philip C, Wynes, Murry W, Mitsudomi, Tetsuya, Weder, Walter, Yankelevitz, David, Herbst, Roy S, Gandara, David R, Carbone, David P, Bunn, Jr, Paul A, Mok, Tony S K, Hirsch, Fred R

“…Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer…”
Get more information

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer by Kian, Waleed, Krayim, Belal, Giles, Betsy, Elkiaan, Nasim A., Idris, Amjad, Fink, Daniel, Peled, Nir, Roisman, Laila C.

“…Background Over the past decade, progress in the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC) has led to the identification of many targeted…”
Get full text